AT A GLANCE:
Focus of Report: Antimicrobial central venous catheters (AMCVCs) are intended to prevent central line-associated bloodstream infections (CLABSIs) by coating or otherwise incorporating external and/or internal surfaces of the catheter with an antimicrobial agent. Some of the compounds used on currently marketed catheters include the antiseptic combination of chlorhexidine and silver sulfadiazine (C-SS); the antibiotic combination of minocycline and rifampicin (M-R); and a compound of silver, platinum, and carbon black (SPC).
Technology Description: AMCVCs are a type of central venous catheter (CVC) coated with antimicrobial agents, such as M-R, C-SS, or SPC.
Health Problem: CLABSIs have a high rate of mortality among hospital-acquired infections. These infections pose such a high risk because patients who require CVCs are usually acutely ill or highly immunosuppressed.
Patient Population: AMCVCs are indicated for short- or long-term use for venous pressure monitoring, blood sampling, administration of drugs and fluids, acute hyperalimentation, and power injection of contrast media.
Evidence Base: A total of 19 studies, including 18 prospective randomized controlled trials (RCTs) and 1 prospective randomized comparative trial evaluating AMCVCs for the prevention of CLABSIs, published from 1997 through January 15, 2018.
Download the report to continue reading…